EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 390 filers reported holding EXELIXIS INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q2 2023 | $6 | -33.3% | 324 | -32.4% | 0.00% | – |
| Q1 2023 | $9 | +12.5% | 479 | -2.6% | 0.00% | – |
| Q4 2022 | $8 | -100.0% | 492 | -66.1% | 0.00% | – |
| Q2 2022 | $30,000 | -42.3% | 1,450 | -36.3% | 0.00% | – |
| Q1 2022 | $52,000 | +20.9% | 2,275 | -3.5% | 0.00% | – |
| Q4 2021 | $43,000 | -43.4% | 2,357 | -24.2% | 0.00% | -100.0% |
| Q3 2021 | $76,000 | +31.0% | 3,110 | -1.8% | 0.00% | – |
| Q2 2021 | $58,000 | -7.9% | 3,167 | +0.9% | 0.00% | – |
| Q1 2021 | $63,000 | 0.0% | 3,140 | 0.0% | 0.00% | – |
| Q4 2020 | $63,000 | -17.1% | 3,140 | +1.0% | 0.00% | -100.0% |
| Q3 2020 | $76,000 | +38.2% | 3,110 | +33.1% | 0.00% | – |
| Q2 2020 | $55,000 | +71.9% | 2,336 | +24.8% | 0.00% | – |
| Q1 2020 | $32,000 | +3.2% | 1,872 | +42.2% | 0.00% | – |
| Q1 2019 | $31,000 | – | 1,316 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |